123 results
Page 4 of 7
8-K
EX-2.1
n37x774skyuch9gjjk
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
425
qqmyc5 hzy1lz
24 Jun 20
Business combination disclosure
4:03pm
425
2jy5dtf axr5mspmqs4
22 Jun 20
Business combination disclosure
5:30pm
8-K
EX-99.2
8h1 8anmwi
22 Jun 20
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
4:55pm
8-K
EX-99.4
toc2ren hq
22 Jun 20
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
4:55pm
8-K
EX-99.1
9q4w1 btkam8a4dm
5 May 20
Invitae Reports More Than $64 Million in Revenue Driven by More Than 154,000 Samples Accessioned in the First Quarter of 2020
4:11pm
8-K
EX-1.1
26gf37lsjua5563ut1
6 Apr 20
Invitae Announces Pricing of Public Offering of Common Stock
5:00pm
8-K
EX-99.1
onvyzhpg5q7649 yjvh
10 Mar 20
Invitae to Acquire YouScript and Genelex to Make it Easier to Use Pharmacogenetic Information at the Point of Care
4:33pm
8-K
EX-99.2
efpghk0 w0xz5sth0la
10 Mar 20
Invitae to Acquire YouScript and Genelex to Make it Easier to Use Pharmacogenetic Information at the Point of Care
4:33pm
8-K
EX-99.1
unb695
19 Feb 20
Invitae Reports $216.8 Million in Annual Revenue Driven by More Than 482,000 Samples in 2019
4:08pm
8-K
EX-99.1
mxsxel
13 Jan 20
Results of Operations and Financial Condition
5:11pm
8-K
EX-99.1
ljnkl7u79njh1 otkzj
13 Nov 19
Invitae to Acquire Clear Genetics
4:09pm
8-K/A
EX-99.1
6wxtc
27 Sep 19
Financial Statements and Exhibits
4:16pm
8-K/A
EX-99.2
li6geee pz0ahcl
27 Sep 19
Financial Statements and Exhibits
4:16pm